AIHTA - Publications - Search - Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma who have undergone complete resection

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma who have undergone complete resection. Oncology Fact Sheet Nr. 99.

[thumbnail of Oncology Fact Sheet Nr.99.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
137kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WR Dermatology
Language:English
Series Name:Oncology Fact Sheet Nr. 99
Deposited on:13 Jun 2022 10:04
Last Modified:13 Jun 2022 10:04

Repository Staff Only: item control page